Clinical Trials Logo

Mixed Oligoastrocytomas clinical trials

View clinical trials related to Mixed Oligoastrocytomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT02023905 Terminated - Low Grade Glioma Clinical Trials

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Start date: March 19, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.